Patients with oligoprogressive metastatic castration-resistant prostate cancer who test positive for circulating tumor DNA (ctDNA) before stereotactic body radiotherapy (SBRT) face significantly shorter progression-free survival, according to a [secondary analysis] published in JAMA Network Open on November 11, 2026.
Researchers analyzed data from 77 patients enrolled in the prospective, nonrandomized TRAP clinical trial. The study examined whether blood-based markers could identify which patients were most likely to benefit from SBRT while continuing treatment with androgen receptor pathway inhibitors (ARPI).
Progression-free survival data
The analysis revealed a stark divide in clinical outcomes based on pretreatment ctDNA status. Among the 19 patients who were ctDNA positive (24.7% of the cohort), the median progression-free survival was 3.0 months, compared with 7.8 months for those who were ctDNA negative.

| Metric | ctDNA Positive | ctDNA Negative |
|---|---|---|
| 6-month survival rate | 21.1% | 58.3% |
| Median progression-free survival | 3.0 months | 7.8 months |
| Median time to next therapy | 15.3 months | 29.6 months |
Clinical implications for radiotherapy
While ctDNA status strongly correlated with progression-free survival, its link to overall survival was less definitive. The median overall survival was 27.2 months for the ctDNA-positive group and 33.6 months for the ctDNA-negative group, a difference that did not reach statistical significance after multivariable adjustment.
Investigators suggest that the earlier relapse observed in ctDNA-positive patients may be due to active metastases that remained undetected by standard imaging.
“These findings suggest that radiotherapy may be considered when ctDNA findings are negative; when ctDNA is detected, an alternative systemic treatment should be used,” said Gerhardt Attard, director of the University College London Cancer Institute, in a statement provided to CancerNetwork.
Trial methodology and limitations
The TRAP trial involved patients with two or fewer progressing metastases receiving 30 Gy of SBRT in five fractions. Plasma samples were collected before treatment and analyzed using the PCF_SELECT next-generation sequencing assay, though these results were not available to clinicians at the time of the intervention.
The study authors acknowledged that the lack of randomization limits the ability to determine whether ctDNA serves as a prognostic factor or a predictive biomarker. The analysis was restricted by a limited number of progression events, which complicated multivariable modeling.
Gerhardt Attard serves as the John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London, where he leads the Treatment Resistance Group. His research focuses on the application of liquid biopsy technology to monitor tumor evolution and treatment response in advanced prostate cancer.
In recognition of his work developing diagnostic and prognostic tools using cutting-edge genomics, he received the Agilent Thought Leader Award. Furthermore, he holds an advanced Cancer Research UK Clinician Scientist award for his efforts in transitioning scientific discoveries into clinically implemented tests to improve patient outcomes.
Questions about prostate cancer biomarkers
What was the primary goal of the TRAP trial analysis?
The researchers aimed to evaluate whether pretreatment ctDNA levels could predict the duration of disease control in patients with oligoprogressive castration-resistant prostate cancer undergoing SBRT.
Why did this study produce different results than the ORIOLE trial?
Investigators said that the ORIOLE trial, which studied hormone-sensitive prostate cancer, did not find a similar association between ctDNA and post-SBRT progression.
They attributed this discrepancy to differences in the disease setting and the sensitivity of the assays used.
How was ctDNA detected in this study?
Plasma samples collected one or two times before SBRT were analyzed using PCF_SELECT, a next-generation sequencing assay designed to identify tumor-specific copy number changes in prostate cancer.
Keep reading